Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (891)	6/12/1998 12:23:00 AM
From: Ed Ajootian	Respond to of 10280

RCMac & Billy, Thanks for the reference. This is a great article. First time I've seen anyone explicitly and categorically state that SEPR was in negotiations with Lily on Prozac. I feel that the market was surmising this was going on but was not certain. This article should pretty much confirm that such discussions are going on. The stock should pick up a couple of points on this IMO. Hopefully none of the big boys will see fit to dump into this hype. The first quarter brochure is out and they say in their that they (finally) started enrolling patients for the Phase II Oxybutynin study during the first quarter. Also, SEPR met with the FDA re: getting other formulations of levalbuterol approved in addition to the nebulizer that is currently under review.